MedTrace Logo

OD-doxy-PNV-COVID-19 Old Drug " DOXY " for Prevention of New Virus " COVID-19 "

NCT04584567 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2021-11-19

No results posted yet for this study

Summary

Given the urgency of having guidelines for the management of COVID-19 in the current epidemic context and the lack of specific pharmacological treatment, Military Health recommends the launch of a multicenter, randomized, double-blind, interventional clinical trial.

The aim of this study is to evaluate the efficacy of a combination of two treatments, low-dose doxcycline (100 mg/day) and Zinc (15 mg/day) (dietary supplement) in the primary prevention of COVID-19 infection in health care professionals in Tunisia compared to two control groups.

Conditions

  • Covid19

Interventions

DRUG

Doxycyclin

daily (100mg)

Sponsors & Collaborators

  • Dacima Consulting

    collaborator OTHER

  • Hedi Gharsallah

    lead NETWORK

Principal Investigators

  • Batikh R Riadh, physican · Military hospital

  • Stambouli N nejla, phd · Military hospital

  • Gharsallah H Hedi, physican · Military hospital

  • Ferjani M Mustapha, physican · Direction de la Santé militaire

  • Ben Moussa M mohamed, physican · Military hospital

  • Youssfi MA Mohamed Al, physican · Military hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2021-02-01
Completion
2021-11-01

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04584567 on ClinicalTrials.gov